Navigation Links
Latest Hyaluronic Acid Filler Takes the Sting Out of Beauty
Date:7/10/2008

N. DALLAS and PLANO, Texas, July 10 /PRNewswire/ -- In the war of the injectable beauty fillers, the battle will soon become heated with the arrival of the newest hyaluronic acid injectable gel filler in the U.S. aesthetics market. Anika Therapeutics' FDA-approved ELEVESS(TM) enters the arena with a clear combat advantage: incorporation of lidocaine with their hyaluronic acid (H.A.) gel, to improve injection comfort.

Many cosmetic physicians, including Jeffrey Adelglass, MD, FACS of SKINTASTIC(TM) Medical & Surgical Rejuvenation Center of Plano, Texas routinely mix lidocaine with some dermal fillers, or inject lidocaine as a nerve-block prior to filler injection, primarily in sensitive, nerve-rich areas such as the lips and eye areas. Elimination of mixing and nerve-blocks saves time and work for the doctor, and reduces the patient's wait.

Although not the first FDA-approved hyaluronic acid filler/lidocaine formulation in the U.S., ELEVESS(TM) claims to provide long-lasting results. Lack of durability is a chief complaint of frequent H.A. filler users. Currently approved for sale in the U.S., European Union and in Canada, ELEVESS(TM) utilizes a proprietary cross-linking technology that creates a highly-concentrated H.A. formulation which suggests the potential of longer durability in the body. Allergan, the makers of Botox(R), currently produce Juvaderm(R) with lidocaine for the European Union, but U.S. approval of their H.A./lidocaine formulation is forthcoming. A U.S. dermal filler already utilizing lidocaine is non-resorbable-ArteFill (a non-H.A. filler) by Artes Medical; Artes was chosen by Anika Therapeutics to be a U.S. distributor for ELEVESS(TM). Dr. Adelglass is a clinical researcher for Artes Medical, and serves on Artes' Scientific Advisory Board.

Experience counts. Dr. Adelglass was the first Texas physician to recently achieve simultaneous Diamond pinnacle-level status as a Botox(R) injector and Triple-Platinum status with Me
'/>"/>

SOURCE SKINTASTIC(TM) Medical and Surgical Rejuvenation Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Licensed Rx Announces Latest Customer Savings Scheme
2. Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future
3. Latest Research Shows Strong Consumer Demand for Organic Foods
4. Cardiologist Praises Latest Resveratrol/Red Wine Research
5. The DataTrace(R) RF System, the Latest High Performance Radio Data Logger for Real-Time, Process Data Collection, Reporting, and Analysis Is Launched
6. Agilysys Announces Latest Version of Lodging Management System(R) (LMS)
7. Cardiva Medical, Inc. to Present at the Investment In Innovation (In3) Medical Device Summit on June 18, 2008 in San Francisco, CA; Announces the Completion of Its Latest Phase in Its US Sales Force Expansion
8. Latest research on allergies: Specific immunotherapy can help
9. Service Employee Unions Latest Attack on RNs Parrots McCains Attack on Obamas Health Plan
10. Latest Advances in Infection Prevention and Control to be Presented in Denver, CO at Worlds Largest Annual Infection Prevention Conference, June 15-19, 2008
11. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... (PRWEB) March 29, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) pending in the U.S. District ... litigation’s next Case Management Conference for April 21st ... meeting will address the progress of product liability ... experienced heart attacks, strokes and other cardiovascular complications ...
(Date:3/29/2015)... March 29, 2015 At this ... platform provides basic health information around medical conditions ... discuss these challenges as well as helping them ... addresses six medical conditions using evidenced based information ... engage in conversations around them., ...
(Date:3/29/2015)... Ore. (PRWEB) March 29, 2015 Youth ... Marion counties in Oregon to assess the feasibility of ... with emotional and behavioral problems and their families. , ... to select participants that will be provided technical assistance ... Oregon counties join six other national awardees chosen by ...
(Date:3/29/2015)... 29, 2015 Final Cut Pro ... from Pixel Film Studios, entitled TranSports. , “TranSports ... for Final Cut Pro X,” said Christiana Austin, CEO ... tools needed to effortlessly transition using this cool sports ... new and uniquely styled transition pack for Final Cut ...
(Date:3/29/2015)... TN (PRWEB) March 29, 2015 North ... several PT Online Continuing Education Courses . ... 10.0 hours of CME - TPTA, approval # 56399TX ... the evaluation of the shoulder complex - 10.5 hours ... Approved #56400TX , Examination and Treatment of the SI ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 2Health News:Krame Health Solutions Announces Release of AfroHealthLink, an Interactive Health Resource Center Tailored to Individuals of African & Caribbean Descent Around the World 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2
... Findings of a recent study suggests hunger may be ... researchers // studied 16 men who agreed to skip breakfast. ... evening. Participants were asked to consume sugary, salty or bitter ... not swallow the drinks, but instead spit them out after ...
... with chemo-resistant leukemia, a new drug is showing promising ... experimenting with bacteria-based recombinant immunotoxins. An immunotoxin is bioengineered ... part of the antibodies that are commonly used to ... encouraging results in a phase II study. ,Researchers ...
... Latest research shows the chickenpox vaccine loses some ... vaccination.// Parents are encouraged to vaccinate their children ... Consequently, researchers were prompted to further investigate the ... individuals. ,Researchers studied nearly 350 children ...
... common form of cancer in the United States. According to ... against colon cancer. In addition, soy protein may help minimize ... fed five different diets to female mice and followed their ... the effects of specific ingredients. Diet one contained milk protein, ...
... get up and get moving. Breast cancer survivors ... body esteem and better mood than sedentary breast ... ,Researchers compared 40 women who said they regularly ... cancer survivors. Regular exercisers reported significantly more positive ...
... depression may have an increased risk of heart disease ... than 93,600 older women who participated in the Women's ... long-term program designed to determine how biological and lifestyle ... and other health conditions. For this study, participants were ...
Cached Medicine News:
(Date:3/27/2015)... , March 27, 2015 According ... Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, ... & Indication (AF, VT, WPW) - Global Forecasts to ... expected to reach around ~$4.73 Billion by 2019 with ... 2014 to 2019. Browse   90 ...
(Date:3/27/2015)... Mass. , March 27, 2015 /PRNewswire/ ... and privately-held MirImmune LLC, today announced that ... agreement to RXi,s novel and proprietary sd-rxRNA® ... cancer immunotherapies. The collaboration has the potential ... patient friendly cancer treatments that could be ...
(Date:3/27/2015)... 27, 2015 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution ... radiotherapy and diagnostic imaging centers in ... a purchase agreement under which Concord Medical Services ... the Company, agreed to acquire the Fortis Surgical ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
Blood sedimentation rate analysis...
Blood sedimentation rate analysis...
The Sedimat 15 Automated sedrate system provides an accurate ESR result in only 15 minutes. Fast, in-office results (before patient leaves the office) can lead to improved patient therapy....
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
Medicine Products: